Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123M
-
Number of holders
-
253
-
Total 13F shares, excl. options
-
81.1M
-
Shares change
-
-1.7M
-
Total reported value, excl. options
-
$949M
-
Value change
-
-$23.4M
-
Put/Call ratio
-
0.94
-
Number of buys
-
110
-
Number of sells
-
-110
-
Price
-
$11.69
Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q3 2023
284 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q3 2023.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 253 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 81.1M shares
of 123M outstanding shares and own 65.87% of the company stock.
Largest 10 shareholders include BlackRock Inc. (15.4M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (8.19M shares), STATE STREET CORP (7.57M shares), VANGUARD GROUP INC (7.05M shares), DIMENSIONAL FUND ADVISORS LP (2.56M shares), GEODE CAPITAL MANAGEMENT, LLC (2.09M shares), ROYCE & ASSOCIATES LP (1.61M shares), NORTHERN TRUST CORP (1.44M shares), JACOBS LEVY EQUITY MANAGEMENT, INC (1.31M shares), and RENAISSANCE TECHNOLOGIES LLC (1.29M shares).
This table shows the top 253 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.